Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. - Wikidata - wikimedia - TriplyDB

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.

http://www.wikidata.org/entity/Q37176312

about

Ultra-Deep Sequencing Characterization of HCV Samples with Equivocal Typing Results Determined with a Commercial Assay.NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.

P2860

Q37377376-338F8E0E-F277-4B95-8491-756ADA17D759 Q40237283-06D78F8F-A14A-47DC-B82A-3D91CC1344C5

P2860

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.

http://www.wikidata.org/entity/Q37176312

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dynamic of Mixed HCV Infection ...... atment With Peg-IFN/Ribavirin.

@en

Dynamic of Mixed HCV Infection ...... atment With Peg-IFN/Ribavirin.

@nl

type

label

Dynamic of Mixed HCV Infection ...... atment With Peg-IFN/Ribavirin.

@en

Dynamic of Mixed HCV Infection ...... atment With Peg-IFN/Ribavirin.

@nl

prefLabel

Dynamic of Mixed HCV Infection ...... atment With Peg-IFN/Ribavirin.

@en

Dynamic of Mixed HCV Infection ...... atment With Peg-IFN/Ribavirin.

@nl

P1433

Q37176312-48093ED3-CC18-43B2-8ACC-F1DBE418C27E

P1476

Q37176312-B1EC0FC0-EB66-4113-A00A-22E90DB3ADFE

P2093

Q37176312-5C21219B-C266-4FE9-A88D-7F28EC2B9BBF

Q37176312-5D6ADF98-A0BB-42BA-B660-618F27D88D69

Q37176312-78132F35-1D36-4E43-8972-978E1C2CB443

Q37176312-EA8C0877-1337-44C5-A4F3-9FC30C757FAA

Q37176312-ED1AC28C-3CDB-447B-B716-15DC210165DA

P2860

Q37176312-08935158-0A45-446C-9758-DD0BA575E99F

Q37176312-0ADA6CF7-845E-4FB4-80B6-C15244F2AACB

Q37176312-0CE62552-0A2B-4A5C-B603-544C4CFA23DA

Q37176312-101BE592-D7E3-4ACF-9D7C-C1D35E1A2DF0

Q37176312-2423E6A5-8DDC-413D-9582-9ACBCFBBCA6D

Q37176312-2916379D-9058-42FF-B78B-D5322AFB4E88

Q37176312-35B5657D-FF5E-4808-B35F-D64064B80C53

Q37176312-3A7FF379-0E56-4DBC-8E8E-643E17530AA8

Q37176312-40B1CFAA-5EF5-4870-A0AE-08B5DE5DCFC8

Q37176312-4F780FA6-D0BB-4FEF-8D78-119AE46B4009

P304

Q37176312-BE7DAAB6-8161-42C9-8F20-13D3609B468E

P31

Q37176312-8AA30FD4-70CB-4DD8-B5F6-B26E285AD68B

P356

Q37176312-E7C4ADC1-C022-40BF-88A4-5D7D47B67573

P407

Q37176312-A497EC90-EAEA-494E-BEB6-8567B8FDEB1B

P433

Q37176312-BFB1E9FE-1C1E-4437-833A-5D1A54D97317

P478

Q37176312-417AD9B1-1392-479B-A51D-E4EB902F4CA4

P50

Q37176312-52FE8B93-2D67-4372-A910-23A681DADCB0

Q37176312-5AD93FD5-A7F7-4E0C-AAD6-C314071AF2EC

Q37176312-6FC47882-3A64-415A-8899-19112CC8F475

Q37176312-9A1F9E3D-EF4C-4C94-9631-D1522CDD3652

Q37176312-9EFF8C34-0772-47BA-94CF-B7665DD46856

Q37176312-DE5B94D7-1E1F-42FB-93F7-E43956D99180

P577

Q37176312-167C7FDC-9D7E-411B-BE7A-9102879EB510

P698

Q37176312-9A136ED2-8BC3-4737-8D57-41DB35F755ED

P932

Q37176312-E0321C4B-BEF8-4E0C-9877-AF09EAA17EAE

P356

MD.0000000000001876

P1433

P1476

Dynamic of Mixed HCV Infection ...... atment With Peg-IFN/Ribavirin.

@en

P2093

Andrea Andolina

http://www.w3.org/2001/XMLSchema#string

Clelia Di Serio

http://www.w3.org/2001/XMLSchema#string

Emanuela Messina

http://www.w3.org/2001/XMLSchema#string

Filippo Trentini

http://www.w3.org/2001/XMLSchema#string

Lucy Porrino

http://www.w3.org/2001/XMLSchema#string

P2860

Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells.

Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5' Untranslated Region Sequences

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

HCV genotyping from NGS short reads and its application in genotype detection from HCV mixed infected plasma

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants.

Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients

Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.

P304

e1876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000001876

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Caterina Uberti-Foppa

Adriano Lazzarin

Sabrina Bagaglio

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26512601

http://www.w3.org/2001/XMLSchema#string

P932

4985415

http://www.w3.org/2001/XMLSchema#string